New test could tell doctors early if breast cancer chemo is failing
NCT ID NCT03524430
Summary
This study is testing a new diagnostic tool called the RNA Disruption Assay (RDA). It aims to see if a small tumor biopsy taken about a month after starting chemotherapy can accurately predict whether the treatment is working to eliminate the cancer. The goal is to help doctors identify patients who are not responding early, so treatment plans can be adjusted sooner for better outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital U. 12 de Octubre
RECRUITINGMadrid, Spain
-
Institut de Cancerologie de Strasbourg
RECRUITINGStrasbourg, France
-
NZOZ Neuromed
RECRUITINGLublin, Poland
-
SST di Cremona Multidisciplinare di Patologia Mammaria, Italy
RECRUITINGCremona, Italy
-
Siteman Cancer Center
RECRUITINGSt Louis, Missouri, 63129, United States
-
Sunnybrook Health Sciences Center
RECRUITINGToronto, Canada
-
Universitätsklinikum Münster
RECRUITINGMünster, Germany
Conditions
Explore the condition pages connected to this study.